Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

629 - Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study


08 Oct 2016


Poster Display


Andrea Casadei Gardini


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


A. Casadei Gardini1, L. Faloppi2, B. Daniele3, S. Cascinu4, S. Lonardi5, G. Masi6, F. Negri7, D. Santini8, N. Silvestris9, V. Zagonel5, M. Scartozzi2

Author affiliations

  • 1 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., 47121 - Meldola/IT
  • 2 Clinica Di Oncologia Medica, University of Cagliari, 60126 - Cagliari/IT
  • 3 Oncology, Azienda Ospedaliera G. Rummo, 82100 - Benevento/IT
  • 4 Medical Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 47121 - Modena/IT
  • 5 Department Of Oncology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 6 Medical Oncology, Azienda Ospedaliera Universitaria S.Chiara, 47121 - Pisa/IT
  • 7 Medical Oncology, Azienda Ospedaliera di Parma, 47121 - Parma/IT
  • 8 Medical Oncology, Libero Istituto Universitario Campus Bio-Medico (LIUCBM), 00118 - Roma/IT
  • 9 Medical Oncology, Istituto Tumori Giovanni Paolo II, 47121 - Bari/IT


Abstract 629


Preclinical data suggested that significant HCC growth is dependent on angiogenesis.In the ALICE-2 we study patients (PT) receiving sorafenib(S) for HIF-1α,VEGF-A and VEGF-C SNPs.At multivariate analysis rs12434438 of HIF-1α,rs2010963 of VEGF-A and rs4604006 of VEGF-C have been confirmed as independent factors for PFS and OS. At the combined analysis of significant SNPs the presence of 2 favourable alleles of VEGF compared to only 1 or to none favourable alleles, identifies three populations with different PFS(respectively:10.8 vs. 5.6 vs. 3.7 months,p 

Trial design

This is a prospective non pharmacological study. The study population consisted of PT with advanced-stage HCC and PT not eligible for locoregional treatments or liver transplantation.The primary aim of the study is to validated the prognostic or predictive role of eNOS,Ang2,HIF-1, VEGF and VEGFR SNPs in relation to clinical outcome of PT treated with S. The secondary aim of the study is to verify the prognostic value of the basal level of ldh, blood pressure, plasma level of Ang2 and plasma level of VEGF in relation to clinical outcome (progression-free survival and overall survival) of patients treated with S. The study was planned to have a 90% power at the 5% significance level (two-sided) to detect a 42% relative reduction in the progression rate (absolute increase in PFS of 2.5 months). Assuming a 24-month accrual period and a 12-month follow-up, 160 patients were required.

Clinical trial identification


Legal entity responsible for the study

Andrea Casadei Gardini




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings